- Main
Multimodal in vivo and postmortem assessments of tau in Lewy body disorders
- Coughlin, David G;
- Phillips, Jeffrey S;
- Roll, Emily;
- Peterson, Claire;
- Lobrovich, Rebecca;
- Rascovsky, Katya;
- Ungrady, Molly;
- Wolk, David A;
- Das, Sandhitsu;
- Weintraub, Daniel;
- Lee, Edward B;
- Trojanowski, John Q;
- Shaw, Leslie M;
- Vaishnavi, Sanjeev;
- Siderowf, Andrew;
- Nasrallah, Ilya M;
- Irwin, David J;
- McMillan, Corey T;
- Initiative, Alzheimer’s Disease Neuroimaging
Published Web Location
https://doi.org/10.1016/j.neurobiolaging.2020.08.003Abstract
We compared regional retention of 18F-flortaucipir between 20 patients with Lewy body disorders (LBD), 12 Alzheimer's disease patients with positive amyloid positron emission tomography (PET) scans (AD+Aβ) and 15 healthy controls with negative amyloid PET scans (HC-Aβ). In LBD subjects, we compared the relationship between 18F-flortaucipir retention and cerebrospinal fluid (CSF) tau, cognitive performance, and neuropathological tau at autopsy. The LBD cohort was stratified using an Aβ42 cut-off of 192 pg/mL to enrich for groups likely harboring tau pathology (LBD+Aβ = 11, LBD-Aβ = 9). 18F-flortaucipir retention was higher in LBD+AB than HC-Aβ in five, largely temporal-parietal regions with sparing of medial temporal regions. Higher retention was associated with higher CSF total-tau levels (p = 0.04), poorer domain-specific cognitive performance (p = 0.02-0.04), and greater severity of neuropathological tau in corresponding regions. While 18F-flortaucipir retention in LBD is intermediate between healthy controls and AD, retention relates to cognitive impairment, CSF total-tau, and neuropathological tau. Future work in larger autopsy-validated cohorts is needed to define LBD-specific tau biomarker profiles.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
-
-